Patents by Inventor Kyle Elrod

Kyle Elrod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazines that inhibit protease cathepsin S and HCV replication
    Patent number: 8106059
    Abstract: The present invention is directed to compounds of formula I, below, that have the dual property of acting as cathepsin S inhibitors and of inhibiting HCV replication. Such compounds are therefore useful in treating disease states that include hepatitis C, Alzheimer's disease, and autoimmune disorders. The present invention is also directed to pharmaceutical compositions containing these compounds, and processes for preparing the compounds.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: January 31, 2012
    Assignee: ViroBay, Inc.
    Inventors: Leslie Jean Holsinger, Kyle Elrod, John O. Link, Michael Graupe, In Jong Kim
  • COMPOUNDS THAT INHIBIT PROTEASE CATHEPSIN S AND HCV REPLICATION
    Publication number: 20090270415
    Abstract: The present invention is directed to compounds that have the dual property of acting as cathepsin S inhibitors and of inhibiting HCV replication. Such compounds are therefore useful in treating disease states that include hepatitis C, Alzheimer's disease, and autoimmune disorders. The present invention is also directed to pharmaceutical compositions containing these compounds, and processes for preparing the compounds.
    Type: Application
    Filed: October 22, 2008
    Publication date: October 29, 2009
    Applicant: ViroBay, Inc.
    Inventors: Leslie Jean Holsinger, Kyle Elrod, John O. Link, Michael Graupe, In Jong Kim
  • Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
    Publication number: 20070141059
    Abstract: The present invention is directed to the use of Cathepsin S inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.
    Type: Application
    Filed: December 10, 2004
    Publication date: June 21, 2007
    Applicant: AXYS Pharmaceuticals, Inc.
    Inventor: Kyle Elrod
  • Metal mediated serine protease inhibitors
    Patent number: 6355460
    Abstract: The present invention relates to serine protease inhibitors having a P site binding moiety and a divalent cation(s) chelating moiety which are pre-prepared as divalent cation(s) complexes or combined with the serine protease in the presence of divalent cation(s) and methods for identifying and using the inhibitors. The compounds are shown to have high inhibitory activity when complexed to divalent cation(s) and are useful in various processes associated with serine protease isolation and inhibition.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: March 12, 2002
    Assignee: Axys Pharmaceuticals, Inc.
    Inventors: James M. Clark, Kyle Elrod, Thomas E. Jenkins, Bradley A. Katz, William R. Moore, Robert M. Stroud
  • Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
    Patent number: 6255091
    Abstract: A method is presented for determining if the inhibition of metal mediated serine proteases can be potentiated by cobalt or zinc ions.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: July 3, 2001
    Assignees: AXYS Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: James M. Clark, Kyle Elrod, Thomas E. Jenkins, Bradley A. Katz, William R. Moore, Robert M. Stroud